Skip to content

13F-HR filed by BB BIOTECH AG

BB BIOTECH AG filed this 13F-HR for the quarter ended 2013-12-31, filed 2014-02-12, with 23 holding rows worth $1,871,688,000.

Accession
0000950123-14-001811
Filed
2014-02-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2013

A holdings report, 23 entries on the cover page, a total value of $1,871,688,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,871,689,000 with VALUE read as thousands by filing date, 13F file number 028-06964. The quarter's positions are built on this report. The resolved quarter.

Other managers

  • included managerBiotech Focus N.V. 028-11193
  • included managerBiotech Invest N.V. 028-11191
  • included managerBiotech Target N.V. 028-11189

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
CELGENE CORP151020104COM2,029,271$342,882,000thousands by filing date
Gilead Sciences,Inc.375558103COM3,547,714$266,433,000thousands by filing date
ISIS PHARMACEUTICALS INC464330109COM6,417,548$255,675,000thousands by filing date
INCYTE CORP COM45337C102Stock4,221,087$213,714,000thousands by filing date
Vertex Pharmaceuticals Incorporated92532F100COM1,404,445$104,350,000thousands by filing date
ALEXION PHARMACEUTICALS INC015351109COM757,428$100,650,000thousands by filing date
MEDIVATION INC58501N101COM1,479,706$94,435,000thousands by filing date
HALOZYME THERAPEUTICS INC COM40637H109Stock4,724,936$70,827,000thousands by filing date
PHARMACYCLICS INC716933106COM636,542$67,333,000thousands by filing date
SYNAGEVA BIOPHARMA CORP87159A103COM858,757$55,579,000thousands by filing date
REGENERON PHARMACEUTICALS COM75886F107Stock192,000$52,846,000thousands by filing date
IMMUNOGEN INC45253H101COMMON STOCK3,225,816$47,323,000thousands by filing date
THERAVANCE INC88338T104COMMON STOCK888,244$31,666,000thousands by filing date
ALNYLAM PHARMACEUTICALS INC COM02043Q107Stock471,288$30,304,000thousands by filing date
CLOVIS ONCOLOGY INC189464100COM488,188$29,423,000thousands by filing date
ENDOCYTE INC29269A102COM2,643,522$28,233,000thousands by filing date
NEUROCRINE BIOSCIENCES INC64125C109COM2,646,552$24,719,000thousands by filing date
INFINITY PHARMACEUTICALS INC45665G303COM1,300,737$17,963,000thousands by filing date
TESARO INC881569107COM471,282$13,309,000thousands by filing date
ARIAD PHARMACEUTICALS INC04033A100COM1,387,171$9,461,000thousands by filing date
IDENIX PHARMACEUTICALS INC45166R204COM1,250,000$7,475,000thousands by filing date
ACHILLION PHARMACEUTICALS IN00448Q201COM1,779,340$5,906,000thousands by filing date
CUBIST PHARMACEUTICALS INC229678123RIGHT 99/99/9999 ADDED876,273$1,183,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-14-001811this filing2014-02-12acceptance time not in the bulk data set